Putting the award page together from the records…
Putting the award page together from the records…
Invirsa, Inc. received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $31.02M obligated so far for r&d- other research and development (advanced development). It runs to 2030-09-04.
Key facts · data as of Oct 23, 2026
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 23, 2026.
Cite this page: SpendQuery, Award 75A50120C00171, data as of Oct 23, 2026, https://spendquery.com/award?id=CONT_AWD_75A50120C00171_7505_-NONE-_-NONE-
Invirsa, Inc.: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3.
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
10 actions since 2023-01-05. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-08-21 | P00013 | Supplemental agreement (work within scope) | $9.00M | ADD ADDITIONAL FUNDING TO CLIN 0003 AND EXTEND THE PERIOD OF PERFORMANCE (POP) OF CLIN 0003 |
| 2026-05-08 | P00012 | Supplemental agreement (work within scope) | $3.64M | ADD ADDITIONAL FUNDING TO CLIN 0001, EXTEND THE POP OF PERFORMANCE OF CLIN 0001, UPDATE FAR AND HHS CLAUSES, AND UPDATE THE SOW |
| 2025-06-18 | P00011 | Supplemental agreement (work within scope) | $15.29M | INVIRSA - EXERCISE CLIN 0003/OPTION 2; UPDATE THE PERIOD OF PERFORMANCE (POP) FOR CLIN 0001, 0002, 0003 & 0004; UPDATE BUDGETS OF CLIN 0003 & 0004; UPDATE SOW; UPDATE FAR CLAUSES |
| 2024-07-17 | P00010 | Funding only | $1.98M | EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. |
| 2024-04-04 | P00009 | Supplemental agreement (work within scope) | $0 | EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. |
| 2023-10-19 | P00008 | Supplemental agreement (work within scope) | $0 | EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. |
| 2023-09-12 | P00007 | Funding only | $1.11M | EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. |
| 2023-05-05 | P00006 | Supplemental agreement (work within scope) | $0 | EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. |
| 2023-04-07 | P00005 | Option exercised | $0 | EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. |
| 2023-01-05 | P00004 | Administrative change | $0 | EO14042 INV-102 FOR THE TREATMENT OF MUSTARD GAS KERATOPATHY UNDER BAA-18-100-SOL-00003, AREA OF INTEREST 5.3. |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-23). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗